132TiP Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC)

Subjects

Subjects :

*INVESTIGATIONAL drugs
*BIOMARKERS
*METASTASIS

Details

Language :

English

ISSN :

09237534

Volume :

33

Database :

Academic Search Index

Journal :

Annals of Oncology

Publication Type :

Academic Journal

Accession number :

159076965

Full Text :

https://doi.org/10.1016/j.annonc.2022.07.164